Clinical Trial: A Study to Assess the Efficacy of Erlotinib for Leptomeningeal Carcinomatosis in EGFR Mutation Positive Non-small Cell Lung Cancer

Study Status: Terminated
Recruit Status: Terminated
Study Type: Interventional

Official Title:

Brief Summary: To assess the efficacy and safety of erlotinib for non-small cell lung cancer patients with leptomeningeal carcinomatosis

Detailed Summary:
Sponsor: Clinical Research Center for Solid Tumor, Korea

Current Primary Outcome: Overall survival [ Time Frame: 1 year ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

  • Cytology negative conversion rate [ Time Frame: 1 month, 2 months, 3 months, 4 months ]
  • Neurologic symptom improvement [ Time Frame: 1 month, 2 months, 3 months, 4 months ]
  • Response rate (extra-cranial disease) [ Time Frame: 2 months, 4 months ]
  • Response rate (brain) [ Time Frame: 2 months, 4 months ]
  • Quality of life [ Time Frame: 1 month, 2 months, 3 months, 4 months ]
  • Toxicities [ Time Frame: 1 month, 2 months, 3 months, 4 months ]
  • Prognostic factors [ Time Frame: N-A ]


Original Secondary Outcome: Same as current

Information By: Clinical Research Center for Solid Tumor, Korea

Dates:
Date Received: January 24, 2009
Date Started: January 2009
Date Completion:
Last Updated: July 25, 2011
Last Verified: July 2011